Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.O)

CPRX.O on Consolidated Issue listed on NASDAQ Capital Market

2.93USD
17 Nov 2017
Change (% chg)

$0.02 (+0.69%)
Prev Close
$2.91
Open
$2.86
Day's High
$2.95
Day's Low
$2.85
Volume
911,539
Avg. Vol
740,798
52-wk High
$3.24
52-wk Low
$1.01

Latest Key Developments (Source: Significant Developments)

Catalyst Pharmaceuticals posts Q3 loss per share $0.05
Wednesday, 8 Nov 2017 04:41pm EST 

Nov 8 (Reuters) - Catalyst Pharmaceuticals Inc :Catalyst Pharmaceuticals announces third quarter 2017 financial results and provides corporate update.Q3 GAAP loss per share $0.05.Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.Catalyst Pharmaceuticals Inc - ‍expects pre-commercialization expenses to increase in Q4 of 2017​.  Full Article

Catalyst Pharmaceuticals completes enrollment in second Phase 3 trial of Firdapse®
Tuesday, 31 Oct 2017 08:03am EDT 

Oct 31 (Reuters) - Catalyst Pharmaceuticals Inc :Catalyst Pharmaceuticals completes enrollment in second Phase 3 trial of Firdapse® in patients with Lambert-Eaton Myasthenic Syndrome.Catalyst Pharmaceuticals Inc - ‍top-line results for Phase 3 trial of Firdapse expected in early December​.  Full Article

Catalyst Pharmaceuticals provides update on the status of its Firdapse development activities
Wednesday, 30 Aug 2017 08:03am EDT 

Aug 30 (Reuters) - Catalyst Pharmaceuticals Inc :Catalyst Pharmaceuticals provides update on the status of its Firdapse development activities.Catalyst Pharmaceuticals Inc - ‍expected NDA submission for Firdapse moves from end of 2017 to Q1 2018​.Catalyst Pharmaceuticals Inc - dosing of first patients in phase 3 trial in early 2018​.Catalyst Pharmaceuticals Inc - expects to complete enrollment "shortly", to announce top-line results from confirmatory phase 3 study (lms-003) in q4 this year.​.  Full Article

Catalyst Pharmaceuticals Q2 GAAP loss per share $0.05
Wednesday, 9 Aug 2017 04:29pm EDT 

Aug 9 (Reuters) - Catalyst Pharmaceuticals Inc :Catalyst pharmaceuticals announces second quarter 2017 financial results and provides corporate update.Q2 GAAP loss per share $0.05.Q2 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.Q2 non-GAAP loss per share $0.05 excluding items.  Full Article

Catalyst Pharmaceuticals files for mixed shelf of up to $150 mln
Wednesday, 12 Jul 2017 05:25pm EDT 

July 12 (Reuters) - Catalyst Pharmaceuticals Inc :Catalyst Pharmaceuticals Inc files for mixed shelf of up to $150 million - SEC filing.  Full Article

Catalyst Pharmaceuticals Q4 non-gaap loss per share $0.05 excluding items
Wednesday, 15 Mar 2017 04:32pm EDT 

Catalyst Pharmaceuticals Inc : Catalyst pharmaceuticals announces fourth quarter and year-end 2016 financial results and provides corporate update . Q4 gaap loss per share $0.05 . Q4 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S . Q4 non-gaap loss per share $0.05 excluding items . Catalyst pharmaceuticals inc- catalyst had no revenues in year 2016 or 2015 .Q4 revenue view $0.00 -- Thomson Reuters I/B/E/S.  Full Article

Catalyst Pharmaceuticals updates on trial for patients with congenital myasthenic syndromes
Thursday, 8 Dec 2016 08:03am EST 

Catalyst Pharmaceuticals Inc : Allowing Adult CMS patients to participate in trial . "Continue to believe that we will report top-line results from this study in second half of 2017" . Number of patients increased to approximately 20 .Provides update on its clinical trial for patients with congenital myasthenic syndromes.  Full Article

Catalyst Pharmaceuticals gets FDA special protocol assessment for phase 3 trial of lems treatment
Monday, 31 Oct 2016 08:03am EDT 

Catalyst Pharmaceuticals Inc : Says intends to conduct its second phase 3 trial (designated as lms-003) at two clinical trial sites . FDA has agreed to allow Catalyst to enroll patients from its expanded access program as study subjects in this second trial .Receives special protocol assessment (SPA) from the FDA for second phase 3 clinical trial evaluating firdapse for the treatment of lems.  Full Article

Catalyst Pharmaceuticals announce Q2 2016 financial results and provides product development update
Tuesday, 9 Aug 2016 04:17pm EDT 

Catalyst Pharmaceuticals Inc : Catalyst Pharmaceuticals announces second quarter 2016 financial results and provides product development update . Q2 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S . Q2 GAAP loss per share $0.06 .Q2 non-GAAP loss per share $0.06 excluding items.  Full Article

Catalyst Pharma finalizes late-stage trial design with FDA for Firdapse
Monday, 13 Jun 2016 08:31am EDT 

Catalyst Pharmaceuticals Inc : Catalyst Pharmaceuticals announces agreement with FDA on confirmatory phase 3 study protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome . Expects to initiate a small, single-center study with Firdapse during second half of 2016 .Existing capital resources are adequate to get us to an accepted NDA submission without need for additional financing.  Full Article

BRIEF-Catalyst Pharmaceuticals posts Q3 loss per share $0.05

* Catalyst Pharmaceuticals announces third quarter 2017 financial results and provides corporate update